Gender differences in pediatric and adolescent melanoma: A retrospective analysis of 4645 cases - 11/01/24
Abstract |
Background |
There is paucity of data on how gender impacts melanoma prognosis in pediatric and adolescent patients.
Objectives |
This study explores gender differences in presentation and survival among pediatric and adolescent patients with melanoma.
Methods |
The National Cancer Database 2004-2018 was queried for cases of primary invasive cutaneous melanoma in pediatric and adolescent patients (birth to 21 years) for a retrospective cohort study.
Results |
Of the 4645 cases, 63.4% were female. Median Breslow depth was 1.05 mm for males (interquartile range 0.50-2.31) and 0.80 mm for females (interquartile range 0.40-1.67; P < .001). Trunk was the most common primary site for females (34.3%) and males (32.9%). More females than males were diagnosed with stage I disease (67.8% vs 53.6%). Males had higher rates of regional lymph node positivity (27.9% vs 18.1%; P < .001) and ulceration (17.1% vs 11.4%; P < .001). Five-year overall survival was 95.9% for females and 92.0% for males (P < .001). After adjusting for confounders, male gender independently increased mortality risk (reference: females; adjusted hazard ratio 1.57; 95% confidence interval 1.32-1.86).
Limitations |
Retrospective study.
Conclusion |
Males exhibited more aggressive pathologic features including greater Breslow thickness and higher ulceration and lymph node positivity rates. Male gender independently increased mortality risk.
Le texte complet de cet article est disponible en PDF.Key words : adolescent, children, female, gender, male, malignancy, melanoma, National Cancer Database, pediatric, sex, skin cancer, survival
Abbreviations used : aHR, CDC, CI, NCDB, OS
Plan
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: The Office of Regulatory Affairs at University of Nebraska Medical Center determined this project does not constitute human subject research as defined at 45CFR46.102. Therefore, it is not subject to federal regulations and does not require Institutional Review Board review. |
Vol 90 - N° 2
P. 280-287 - février 2024 Retour au numéro
Article précédent
- Best practices in the treatment of melasma with a focus on patients with skin of color
- Seemal R. Desai, Andrew F. Alexis, Nada Elbuluk, Pearl E. Grimes, Jonathan Weiss, Iltefat H. Hamzavi, Susan C. Taylor
- Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma
- Guihong Wan, Bonnie W. Leung, Mia S. DeSimone, Nga Nguyen, Ahmad Rajeh, Michael R. Collier, Hannah Rashdan, Katie Roster, Xu Zhou, Cameron B. Moseley, Ajit J. Nirmal, Roxanne J. Pelletier, Zoltan Maliga, Gyorgy Marko-Varga, István Balázs Németh, Hensin Tsao, Maryam M. Asgari, Alexander Gusev, Anna M. Stagner, Christine G. Lian, Marc S. Hurlbert, Feng Liu, Kun-Hsing Yu, Peter K. Sorger, Yevgeniy R. Semenov
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?